UK markets closed

Elite Pharmaceuticals, Inc. (ELTP)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.1298+0.0006 (+0.49%)
At close: 02:35PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 132.12M
Enterprise value 134.19M
Trailing P/E 6.91
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.79
Price/book (mrq)2.85
Enterprise value/revenue 2.84
Enterprise value/EBITDA -413.45

Trading information

Stock price history

Beta (5Y monthly) -0.14
52-week change 3333.33%
S&P500 52-week change 322.38%
52-week high 30.2100
52-week low 30.0300
50-day moving average 30.1438
200-day moving average 30.1249

Share statistics

Avg vol (3-month) 3944.01k
Avg vol (10-day) 3511.79k
Shares outstanding 51.02B
Implied shares outstanding 61.02B
Float 8797.53M
% held by insiders 122.23%
% held by institutions 10.00%
Shares short (30 Apr 2009) 4757.07k
Short ratio (30 Apr 2009) 40.87
Short % of float (30 Apr 2009) 4N/A
Short % of shares outstanding (30 Apr 2009) 42.16%
Shares short (prior month 31 Mar 2009) 41.34M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Mar 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 32.87%
Operating margin (ttm)22.73%

Management effectiveness

Return on assets (ttm)6.83%
Return on equity (ttm)40.62%

Income statement

Revenue (ttm)47.32M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)68.00%
Gross profit (ttm)N/A
EBITDA 8.3M
Net income avi to common (ttm)15.55M
Diluted EPS (ttm)0.0200
Quarterly earnings growth (yoy)-76.20%

Balance sheet

Total cash (mrq)5.82M
Total cash per share (mrq)0.01
Total debt (mrq)7.89M
Total debt/equity (mrq)16.99%
Current ratio (mrq)1.94
Book value per share (mrq)0.05

Cash flow statement

Operating cash flow (ttm)-2.37M
Levered free cash flow (ttm)-2.5M